ClinicalTrials.gg
RecruitingNCT07448623Updated Apr 13, 2026

A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.

A Phase 1 interventional study of Coramitug in Transthyretin Amyloid Cardiomyopathy, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Netherlands. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Study summary

The study is conducted in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a heart disease that occurs in people with the disease ATTR amyloidosis. The purpose of this study is to see how radioactively labelled coramitug is taken up by the heart after administration through an infusion (Cohort 1), and to understand the extent to which coramitug can be displaced by radioactively labelled coramitug (Cohort 2). In this study it will also be investigated how safe coramitug is and how well it is tolerated when it is used by participants with ATTR-CM. Coramitug is potentially a new medicine for participants with ATTR-CM. Coramitug is a monoclonal antibody that potentially binds to the accumulations of the transthyretin protein and promotes its removal from the heart. It may also prevent the formation of clumps and may help with clearing existing clumps of the abnormal protein. The study will take a maximum of 85 days (for Cohort 1) or 106 days (for Cohort 2) when participating in Period A from the screening until the follow-up visit.

02

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Male or female.
  • Age greater than or equal to (≥) 60 years or above at the time of signing the informed consent.
  • For participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM):
  • Have an established diagnosis of ATTR-CM, with either wild-type Transthyretin (TTR) or variant TTR genotype (ATTRwt) or (ATTRv), with cardiac amyloid infiltration, increased left ventricular (LV) wall thickness, \& heart failure (HF):

    a) Cardiac amyloid infiltration demonstrated by: i. Cardiac positive for TTR amyloid, OR ii. Grade 2 or Grade 3 cardiac uptake at pyrophosphate/3,3-diphosphono-1,2-propanodicarboxylic acid/hydroxymethylene diphosphonate (PYP/DPD/HMDP) scintigraphy with Single-Photon Emission Computed Tomography (SPECT/CT) combined with an extracardiac biopsy positive for TTR amyloid, OR iii. Grade 2 or Grade 3 cardiac uptake at PYP/DPD/HMDP scintigraphy with SPECT/CT combined with normal serum free light chain ratio \& negative serum \& urine immunofixation (Serum Immunofixation [SPIE] and Urine Immunofixation [UPIE]) Note: Bone tracer scintigraphy using 99m technetium (Tc)-labelled pyrophosphate (99mTc-PYP)/99mTc-labelled 3,3-diphosphono-1,2- propanodicarboxylic acid (99mTc-DPD)/99mTc-labeled hydroxymethylene diphosphonate (99m-Tc-HMDP) b. Increased LV wall thickness, as assessed by echocardiography showing LV posterior and septal wall thickness greater than or equal to (≥)13 millimeter (mm) for women and ≥ 14 mm for men (Note: Pre-existing echocardiogram up to 2 years old can be used).

    c. Chronic HF with: i. At least 1 documented hospitalisation for HF occurring greater than (>) 3 months but less than (\<) 2 years, OR ii. History of HF manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath, signs of pulmonary con-gestion on x-ray or auscultation, or peripheral oedema) requiring ongoing treatment with a loop diuretic.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Previous participation in this study. Participation is defined as signed .
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of .
  • Current participation (i.e., signed informed consent) in any other interventional clinical study.
  • Participation in research studies involving exposure to radiation within a year preceding the screening period in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    The cohort includes participants that will be evaluated for the cardiac uptake of 89Zr coramitug.

    Drug: Coramitug

  • Experimental
    Cohort 2

    The cohort includes participants to evaluate the sink effect (if observed in cohort 1) and also evaluate competitive binding between 89Zr-coramitug and different dose levels of coramitug.

    Drug: Coramitug

Interventions

  • DrugCoramitug

    Coramitug will be administered intravenously

06

What researchers measure

Primary outcomes

  1. Mean Standard Uptake Value Ratio (SUVRmean) in myocardium

    Measured as ratio.

    Time frame: Day 1-day 8

  2. Net uptake rate constant (Ki) in myocardium

    Measured as milliliter per minute per centimeter cube (mL/min/cm\^3).

    Time frame: 0 to 168 hours

  3. Change in SUVRmean in myocardium

    Measured as percentage (%).

    Time frame: From baseline to week 52 (day 364), or week 60 (day 420) if there is no uptake expected/observed when both unradiolabelled and radiolabelled compounds are administered together

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    microcurie (μCi)

    Time frame: 0 to 168 hours

  2. Time at which maximum plasma concentration is observed (Tmax)

    Measured in hours.

    Time frame: 0 to 168 hours

  3. Area under the curve (AUC)

    Measured in microcurie \*hours (μCi\*h).

    Time frame: 0 to 168 hours

  4. Terminal half-life (T1/2)

    Measured in hours.

    Time frame: 0 to 168 hours

  5. Cmax

    Measured in nanograms per milliliter (ng/mL).

    Time frame: 0 to 168 hours for cohort 1, 0 to 672 hours for cohort 2

  6. Tmax

    Measured in hours.

    Time frame: 0 to 168 hours for cohort 1, 0 to 672 hours for cohort 2

  7. AUC

    Measured in nanograms\*hours per milliliter (ng\*h/mL).

    Time frame: 0 to 168 hours for cohort 1, 0 to 672 hours for cohort 2

  8. T1/2

    Measured in hours.

    Time frame: 0 to 168 hours for cohort 1, 0 to 672 hours for cohort 2

  9. Number of Treatment Emergent Adverse Events (TEAE)

    Measured as count of events.

    Time frame: From day 1 to day 8 in cohort 1 or day -1 to day 28 for cohort 2

  10. Number of Treatment Emergent Adverse Events

    Measured as count of events.

    Time frame: From baseline to week 52 (day 364), or week 64 (day 448) if there is no uptake expected/observed when both unradiolabelled and radiolabelled compounds are administered together

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for May 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 4, 2026
StartActual
Mar 2, 2026
Primary completionEst.
May 30, 2027
CompletionEst.
Jul 25, 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07448623
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Mar 2, 2026
Primary completion
May 30, 2027 (estimated)
Completion
Jul 25, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion